Potential Benefits & Side Effects Observations from preclinical and limited clinical literature
This product is intended exclusively for laboratory research and should be handled with appropriate safety protocols
UK Regulation: Where the Line Is In the UK, any peptide supplied for human treatment is treated as a medicine and must have MHRA authorisation for specific indications, or be prescribed on a tightly defined specials basis where no licensed alternative exists
Why its notable: animal and preclinical studies support BPC-157s role in mucosal and soft-tissue healing, and its become a go-to for patients with digestive issues or slow-healing soft-tissue injuries
Musculoskeletal and Soft Tissue Research Animal models have shown that BPC-157 may support the healing of muscles, tendons, ligaments, and nerves, potentially by enhancing angiogenesis, reducing inflammation, and stimulating fibroblast activity
Semaglutide activates GLP-1 receptors in the brain and gut